{"id":3297,"date":"2026-02-11T16:06:34","date_gmt":"2026-02-11T19:06:34","guid":{"rendered":"https:\/\/sites.uel.br\/hu-londrina\/?p=3297"},"modified":"2026-02-12T13:48:04","modified_gmt":"2026-02-12T16:48:04","slug":"hu-uel-londrina-inicia-aplicacao-do-nirsevimabe-para-prevencao-do-vsr-em-recem-nascidos","status":"publish","type":"post","link":"https:\/\/sites.uel.br\/hu-londrina\/categoria-noticias\/2026\/02\/11\/hu-uel-londrina-inicia-aplicacao-do-nirsevimabe-para-prevencao-do-vsr-em-recem-nascidos\/","title":{"rendered":"HU-UEL de Londrina inicia aplica\u00e7\u00e3o do Nirsevimabe para preven\u00e7\u00e3o do VSR em rec\u00e9m-nascidos"},"content":{"rendered":"\n<p>A Maternidade do Hospital Universit\u00e1rio (HU) da UEL deu in\u00edcio na \u00faltima ter\u00e7a-feira, 10, \u00e0s primeiras aplica\u00e7\u00f5es do imunobiol\u00f3gico Nirsevimabe, anticorpo de dose \u00fanica, indicado para a preven\u00e7\u00e3o do v\u00edrus sincicial respirat\u00f3rio (VSR) importante fator de interna\u00e7\u00f5es em beb\u00eas.<\/p>\n\n\n\n<p>O Nirsevimabe reduz significativamente casos graves de bronquiolite e pneumonia causadas pelo VSR, al\u00e9m de oferecer prote\u00e7\u00e3o logo ap\u00f3s a administra\u00e7\u00e3o, sem a necessidade de estimular previamente o organismo a desenvolver resposta imunol\u00f3gica ao longo do tempo. O medicamento passou a ser ofertado pelo Minist\u00e9rio da Sa\u00fade e incorporado \u00e0s a\u00e7\u00f5es do Sistema \u00danico de Sa\u00fade (SUS), ampliando a prote\u00e7\u00e3o de rec\u00e9m-nascidos e crian\u00e7as eleg\u00edveis em todo o pa\u00eds.<\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" data-id=\"3299\" src=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02-1024x683.jpg\" alt=\"\" class=\"wp-image-3299\" style=\"width:500px\" srcset=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02-1024x683.jpg 1024w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02-300x200.jpg 300w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02-768x512.jpg 768w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02-1536x1024.jpg 1536w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-02.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Primeira aplica\u00e7\u00e3o do imunobiol\u00f3gico Nirsevimabe no HU<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" data-id=\"3298\" src=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1-1024x683.jpg\" alt=\"\" class=\"wp-image-3298\" style=\"width:500px\" srcset=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1-1024x683.jpg 1024w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1-300x200.jpg 300w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1-768x512.jpg 768w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1-1536x1024.jpg 1536w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/Vacina-Sinsinal-01-1.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\">Primeira aplica\u00e7\u00e3o do imunobiol\u00f3gico Nirsevimabe no HU<\/figcaption><\/figure>\n<\/figure>\n\n\n\n<p>A primeira etapa, contou com 28 beb\u00eas imunizados provenientes dos setores da UTI Neonatal, UCI Neonatal, Unidade Canguru e Alojamento Conjunto. A estrat\u00e9gia \u00e9 direcionada a rec\u00e9m-nascidos prematuros com idade gestacional de at\u00e9 36 semanas e seis dias, al\u00e9m de crian\u00e7as de at\u00e9 23 meses que apresentem comorbidades espec\u00edficas, como cardiopatia cong\u00eanita, broncodisplasia pulmonar, imunocomprometimento grave, s\u00edndrome de Down, fibrose c\u00edstica, doen\u00e7as neuromusculares e anomalias cong\u00eanitas das vias a\u00e9reas.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"768\" height=\"1024\" src=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/foto-beyfortus-semnome-01-1-768x1024.png\" alt=\"\" class=\"wp-image-3301\" style=\"width:500px\" srcset=\"https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/foto-beyfortus-semnome-01-1-768x1024.png 768w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/foto-beyfortus-semnome-01-1-225x300.png 225w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/foto-beyfortus-semnome-01-1-1152x1536.png 1152w, https:\/\/sites.uel.br\/hu-londrina\/wp-content\/uploads\/2026\/02\/foto-beyfortus-semnome-01-1.png 1200w\" sizes=\"auto, (max-width: 768px) 100vw, 768px\" \/><figcaption class=\"wp-element-caption\">Beyfortus Nirsevimabe<br><\/figcaption><\/figure>\n<\/div>\n\n\n<p>Todos os beb\u00eas prematuros nascidos ao longo do ano ser\u00e3o contemplados com a aplica\u00e7\u00e3o do Nirsevimabe. J\u00e1 os beb\u00eas nascidos a termo que apresentem comorbidades eleg\u00edveis receber\u00e3o o imunobiol\u00f3gico durante o per\u00edodo de sazonalidade do VSR, compreendido entre os meses de fevereiro a agosto.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O Nirsevimabe reduz significativamente casos graves de bronquiolite e pneumonia causadas pelo VSR.<\/p>\n","protected":false},"author":9,"featured_media":3299,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3297","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-categoria-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/posts\/3297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/comments?post=3297"}],"version-history":[{"count":3,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/posts\/3297\/revisions"}],"predecessor-version":[{"id":3307,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/posts\/3297\/revisions\/3307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/media\/3299"}],"wp:attachment":[{"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/media?parent=3297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/categories?post=3297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sites.uel.br\/hu-londrina\/wp-json\/wp\/v2\/tags?post=3297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}